StreetAlpha.app
Home › Stocks › SCYX

Scynexis Inc (SCYX)

$2.85
▼ −2.90%
LAST CLOSE · NOV 17

SCYNEXIS develops antifungal drugs for hard to treat fungal infections, aimed at hospital patients and the physicians who treat them. It last closed at $2.85 on Nov 17, down 2.90% on the day.

AI Auto Pilots
Is SCYX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$18.9M
+544.0% vs a year ago
Net income
−$10.1M
−53.5% margin
Operating margin
−126.9%
−$24.0M operating income
Valuation
Market cap
$28.4M
10.0M shares
P/E
–
Price to sales
1.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$8.2M
At Sep 30
Shareholder equity
$59.0M
Shares outstanding
10.0M
At Nov 1
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $13.2M$13.2MFY2021FY2022: $5.1M$5.1MFY2022FY2023: $140.1M$140.1MFY2023FY2024: $3.7M$3.7MFY2024FY2025: $20.6M$20.6MFY2025

From SCYX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated SCYX in the past 90 days.
Average 12-month target
No price targets on SCYX in the past 90 days.
Latest rating changes
GuggenheimMaintained
Aug 13Buy$33
DateFirmActionRatingPrice target
Aug 13GuggenheimMaintainedBuy$33
Loading…

Technical Analysis

SCYX · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 26% below its 20 day and 44% below its 50 day average. It is 89% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot at $2.83, and the nearest resistance the Pivot R1 at $2.97.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 9.2%/day
Key levels
$9.1252 week high+220.0%
$5.40200 day average+89.5%
$4.43100 day average+55.4%
$4.1150 day average+44.2%
$3.98Swing high (Oct 21)+39.6%
$3.5920 day average+26.0%
$2.97Pivot R1+4.2%
$2.85Last close
$2.83Pivot−0.7%
$2.72Pivot S1−4.6%
$2.7052 week low−5.3%
Indicators
RSI (14)25.36Oversold below 30Oversold
MACD-0.30Below its signal lineBearish
Stochastic9.4Near the bottom of its rangeOversold
ADX (14)28.4Trending down
Williams %R-88.8Oversold below −80, overbought above −20Oversold
CCI (20)-197.5Oversold below −100, overbought above 100Oversold
Rate of change−27.7%Change over 10 sessionsBearish
ATR (14)$0.26Typical daily range, 9.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SCYX

What happened before

See how SCYX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SCYX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SCYX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SCYX in the last 90 days.

Loading…

See today’s whale options flow across the market →

SCYX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼14 buying vs 18 selling
  • ▼Held by funds -4.9 pts
  • ▲Funds holding +2
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4240+5.0%
In funds' top 1000–
Held by funds46.8%51.7%−4.9 pts
New / increased7 / 740 / 0−65.0%
Reduced / sold out13 / 50 / 44−59.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SCYX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SCYX is in one of them and how their past SCYX trades turned out.

SCYX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SCYX in an article yet. Here's the latest on the wider market.

About Scynexis

SCYNEXIS is a pharmaceutical company based in Jersey City, New Jersey, that develops antifungal medicines. Its approved product, BREXAFEMME, treats vaginal yeast infections, and it has been licensed to GSK. Its main development candidate, SCY-247, is an oral and intravenous antifungal being studied for serious fungal infections, mainly in hospital patients with weakened immune systems and in other patients at high risk. The company's customers are mainly physicians at major medical centers who treat these patients.

Headquarters
Jersey City, NJ